Richard W Simpson

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 586 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE^-/- mouse model

Tracey A. Gaspari, Hongbin Liu, Iresha Welungoda et al. · Diabetes and Vascular Disease Research · 2011 · 193 citations

A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules

Hongbin Liu, Anthony E. Dear, Lotte Bjerre Knudsen et al. · Journal of Endocrinology · 2009 · 183 citations · Full text

The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE^−/− mouse model

Tracey A. Gaspari, Iresha Welungoda, Robert E. Widdop et al. · Diabetes and Vascular Disease Research · 2013 · 139 citations

Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis

Tracey A. Gaspari, Iressa Spizzo, Hongbin Liu et al. · Diabetes and Vascular Disease Research · 2017 · 133 citations · Full text